Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

[1]  M. Konopleva,et al.  Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm , 2019, The New England journal of medicine.

[2]  M. Konopleva,et al.  More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. , 2019, The New England journal of medicine.

[3]  M. Konopleva,et al.  Early detection of transformation to BPDCN in a patient with MDS , 2018, Experimental Hematology & Oncology.

[4]  P. A. Futreal,et al.  Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. , 2018, Blood.

[5]  M. Konopleva,et al.  Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2017 .

[6]  C. Caux,et al.  BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells , 2017, Nature Communications.

[7]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[8]  A. Letai,et al.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. , 2017, Cancer discovery.

[9]  M. Huynen,et al.  Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function , 2016, Cell reports.

[10]  Meredith O'Keeffe,et al.  Plasmacytoid dendritic cells are short-lived: reappraising the influence of migration, genetic factors and activation on estimation of lifespan , 2016, Scientific Reports.

[11]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[12]  L. Staudt,et al.  Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. , 2015, Immunity.

[13]  M. Colonna,et al.  The multifaceted biology of plasmacytoid dendritic cells , 2015, Nature Reviews Immunology.

[14]  Erinna F. Lee,et al.  Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells , 2015, Proceedings of the National Academy of Sciences.

[15]  Ling Zhang,et al.  Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[16]  T. Lawrence,et al.  Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming , 2014, The EMBO journal.

[17]  J. Cigudosa,et al.  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm , 2014, Leukemia.

[18]  Endi Wang,et al.  Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. , 2014, Archives of pathology & laboratory medicine.

[19]  M. Kortylewski,et al.  Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. , 2014, Blood.

[20]  L. Jeffrey Medeiros,et al.  TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.

[21]  S. Pileri,et al.  Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition , 2014, Leukemia.

[22]  F. Jardin,et al.  Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance , 2013 .

[23]  Philip C. Biggin,et al.  Mutationmapper: A Tool to Aid the Mapping of Protein Mutation Data , 2013, PloS one.

[24]  J. Ransom,et al.  LAMP5 distribution in and on plasmacytoid dendritic cells (P5019) , 2013, The Journal of Immunology.

[25]  S. Pileri,et al.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study , 2013, Haematologica.

[26]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[27]  P. Brousset,et al.  BAD-LAMP is a novel biomarker of nonactivated human plasmacytoid dendritic cells. , 2011, Blood.

[28]  M. J. Ruiz,et al.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. , 2011, Blood.

[29]  F. Jardin,et al.  TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm , 2011, British journal of haematology.

[30]  M. Caligiuri,et al.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[32]  R. Pfeiffer,et al.  Risks of myeloid malignancies in patients with autoimmune conditions , 2009, British Journal of Cancer.

[33]  V. Pascual,et al.  The innate immune system in SLE: type I interferons and dendritic cells , 2008, Lupus.

[34]  M. Teitell,et al.  TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. , 2003, Blood.

[35]  B. Drénou,et al.  Clinical and biologic features of CD4(+)CD56(+) malignancies. , 2002, Blood.

[36]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[37]  P. Leder,et al.  Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia , 1996, Nature Medicine.

[38]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[39]  Chieh-Yu Liu,et al.  Clinical Trials and Observations , 2022 .

[40]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..